A Study to Investigate the Safety and Biodistribution of a Single Intrathecal (IT) Injection of INS1201 in Ambulatory Males With Duchenne Muscular Dystrophy (DMD)

Recruiting

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(9 sites)

United States

USA012, Little Rock, Arkansas

USA010, Davis, California

USA002, Palo Alto, California

USA005, San Diego, California

Rare Disease Research (USA004), Atlanta, Georgia

USA008, Rochester, New York

USA006, Columbus, Ohio

USA001, Memphis, Tennessee

USA015, Norfolk, Virginia